EUVIMEDEUVIMED entdecken
Crossref

Healthcare professionals' experience with early‐stage (stage 1 and 2) type 1 diabetes and readiness for immunotherapies in adults: A UK ‐based survey

Younes R Younes iD, Rachel E J Besser iD, Rabbi Swaby iD, Emma G Wilmot iD, Sarah H Wild iD, Parth Narendran iD, Kathleen M Gillespie iD, Alistair Lumb iD, Ketan Dhatariya iD, Naresh Kanumilli iD, Benjamin C T Field iD

Diabetic Medicine · 08.11.2026

DOI: 10.1111/dme.70528 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetic Medicine, online erschienen am 08.11.2026. Verfasst von Younes R Younes und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes and Endocrinology, Surrey & Sussex Healthcare NHS Trust, Redhill, UK. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Type 1 diabetes progresses through presymptomatic early stages defined by islet autoantibody positivity and glycaemia. Early detection reduces ketoacidosis and facilitates access to disease‐modifying therapies. The extent to which autoantibody screening and follow‐up have been adopted in UK clinical practice for adults is uncertain.

Methods

We conducted a web‐based survey of members of the Association of British Clinical Diabetologists (ABCD), Diabetes Technology Network UK (DTN‐UK) and Primary Care Diabetes and Obesity Society (PCDOS) between 12 December 2025 and 2 February 2026.

Results

Of 164 complete responses, 116 (71%) were from doctors, 40 (24%) from nurses and 8 (5%) from other healthcare professionals. The majority were from district general hospitals ( n = 91, 56%), followed by tertiary centres ( n = 31, 19%), community‐based and private specialist diabetes services ( n = 14, 9%) and general practice ( n = 28, 17%). Thirty‐five per cent (11/31) in tertiary centres and 21% (22/105) in other care settings reported experience in managing adults with early‐stage T1D. Among these clinicians, HbA1c was the most commonly used follow‐up method (73% in tertiary centres and 86% in other settings), while approximately half offered capillary blood glucose and ketone meters and/or continuous glucose monitoring. In general practice, access to islet autoantibody testing was limited, and few had local guidelines for managing stage 1 or 2 T1D. In diabetes specialist practice, autoantibodies to GAD, IA‐2 and ZnT8, but not insulin, were the most widely requested islet autoantibody assays. Perceived readiness to implement immunotherapy was low across all settings.

Conclusions

Early‐stage T1D management is evolving within UK clinical practice. Monitoring and management practices broadly align with consensus recommendations. Education, national guidance and clear commissioning frameworks will be essential for successful provision of immunotherapies.

Schlagwörter

Stichwörter der Autor:innen

early‐stage type 1 diabetesimmunotherapyislet autoantibodiesmonitoringscreening

Autor:innen und Institutionen

  • Department of Diabetes and Endocrinology, Surrey & Sussex Healthcare NHS Trust, Redhill, UK.
  • Diabetes and Inflammation Laboratory, Centre for Human Genetics, Nuffield Department of Medicine, Bukhman Centre for Research Excellence in Type 1 Diabetes, NIHR Oxford Biomedical Research Centre, University of Oxford,…
  • Nottingham Children's Hospital, Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Diabetes Department, University Hospitals of Derby and Burton NHS FT, Derby, UK.
  • Translational Medical Sciences, University of Nottingham, Nottingham, UK.
  • Usher Institute, School of Population Health Sciences, University of Edinburgh, Edinburgh, UK.

ORCID-Profile: Younes R Younes, Rachel E J Besser, Rabbi Swaby, Emma G Wilmot, Sarah H Wild, Parth Narendran, Kathleen M Gillespie, Alistair Lumb, Ketan Dhatariya, Naresh Kanumilli, Benjamin C T Field

Zitieren

APA

Younes, Y. R., Besser, R. E. J., Swaby, R., Wilmot, E. G., Wild, S. H., Narendran, P., Gillespie, K. M., Lumb, A., Dhatariya, K., Kanumilli, N., & Field, B. C. T. (2026). Healthcare professionals' experience with early‐stage (stage 1 and 2) type 1 diabetes and readiness for immunotherapies in adults: A UK ‐based survey. Diabetic Medicine. https://doi.org/10.1111/dme.70528

Vancouver

Younes YR, Besser REJ, Swaby R, Wilmot EG, Wild SH, Narendran P, et al. Healthcare professionals' experience with early‐stage (stage 1 and 2) type 1 diabetes and readiness for immunotherapies in adults: A UK ‐based survey. Diabetic Medicine. 2026. doi:10.1111/dme.70528

BibTeX
@article{Younes2026,
  author = {Younes, Younes R and Besser, Rachel E J and Swaby, Rabbi and Wilmot, Emma G and Wild, Sarah H and Narendran, Parth and Gillespie, Kathleen M and Lumb, Alistair and Dhatariya, Ketan and Kanumilli, Naresh and Field, Benjamin C T},
  title = {Healthcare professionals' experience with early‐stage (stage 1 and 2) type 1 diabetes and readiness for immunotherapies in adults: A UK ‐based survey},
  journal = {Diabetic Medicine},
  year = {2026},
  doi = {10.1111/dme.70528}
}
Kostenlos starten →